Bivalent Moderna
Phase 3Biologic
Bivalent Moderna is one of 22 biologic programs targeting COVID-19. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Bivalent Moderna
MMurdoch Childrens Research Institute
Phase 3
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bivalent Moderna. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details